• Crossject signed a partenering agreement for its ZENEO® Methotrexate product

    Crossject signed a commercial partnership with Sayre Therapeutics, a company specialized in innovative treatments and medical devices commercialization in South Asia. They both agreed to provide Sayre Therapeutics with exclusive distribution and marketing rights in India, Bangladesh, Sri Lanka and Nepal. In return, Crossject will receive a share from 20% to 40% of the revenues generated from the product and Sayre has committed to minimum levels of volumes and marketing investment.  The marketing authorization filing for this innovative product, aimed at treating rheumatoid arthritis, is anticipated early 2017 in the region.

    Read more
  • Crossject Newsletter N°3

    -Supergenerics : lastest developments
    -Stronger Intellectual Property Position
    -"Inventions and men", M6 - 17/06/2015
    -Positive feedbacks from the USA
    -Next event

    Read more


  • 09/10/2015

    Crossject will be present at BIO Pharm America 2015

    Crossject will be present at BIOPHARM AMERICA 2015, the 8th Annual International Partnering Conference, from 15 to 17 September 2015. BIOPharm America™ is where biotech industry partnerships get started, with biotech and pharma executives from around the world. Close to 900 attendees are expected to participate in this Conference.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 09/09/2015

    MidCap Event Paris

    Crossject will meet institutional investors on the occasion of Large and Midcap Event in Paris, October 7 and 8, 2015.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / skype id: timotheemuller 

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos